Dermira Inc (DERM) Shares Bought by Platinum Investment Management Ltd.

Platinum Investment Management Ltd. lifted its stake in shares of Dermira Inc (NASDAQ:DERM) by 60.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 92,400 shares of the biopharmaceutical company’s stock after purchasing an additional 34,700 shares during the period. Platinum Investment Management Ltd. owned about 0.22% of Dermira worth $2,494,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. BNP Paribas Arbitrage SA raised its stake in Dermira by 2,220.7% during the second quarter. BNP Paribas Arbitrage SA now owns 4,154 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 3,975 shares during the period. Quantbot Technologies LP raised its stake in Dermira by 75.4% during the third quarter. Quantbot Technologies LP now owns 5,371 shares of the biopharmaceutical company’s stock worth $145,000 after acquiring an additional 2,309 shares during the period. SG Americas Securities LLC raised its stake in Dermira by 66.8% during the second quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock worth $160,000 after acquiring an additional 2,203 shares during the period. Legal & General Group Plc raised its stake in Dermira by 16.3% during the first quarter. Legal & General Group Plc now owns 6,861 shares of the biopharmaceutical company’s stock worth $236,000 after acquiring an additional 963 shares during the period. Finally, Ardsley Advisory Partners acquired a new stake in Dermira during the second quarter worth about $291,000. 99.54% of the stock is currently owned by institutional investors and hedge funds.

In related news, insider Eugene A. Bauer sold 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 11th. The shares were sold at an average price of $30.04, for a total transaction of $225,300.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Thomas G. Wiggans sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $27.52, for a total transaction of $137,600.00. The disclosure for this sale can be found here. Insiders have sold 28,800 shares of company stock worth $809,425 in the last quarter. Company insiders own 13.30% of the company’s stock.

Dermira Inc (DERM) opened at $24.21 on Wednesday. Dermira Inc has a 12 month low of $21.35 and a 12 month high of $38.75. The company has a current ratio of 4.68, a quick ratio of 4.68 and a debt-to-equity ratio of 1.40.

DERM has been the topic of several research reports. BidaskClub lowered shares of Dermira from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 10th. Zacks Investment Research upgraded shares of Dermira from a “sell” rating to a “hold” rating in a research note on Thursday, August 17th. Mizuho restated a “buy” rating and issued a $43.00 price target (up previously from $40.00) on shares of Dermira in a research note on Thursday, September 7th. Needham & Company LLC restated a “buy” rating and issued a $46.00 price target on shares of Dermira in a research note on Sunday, September 17th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $45.00 price target on shares of Dermira in a research note on Tuesday, September 26th. Four equities research analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $43.33.

TRADEMARK VIOLATION WARNING: “Dermira Inc (DERM) Shares Bought by Platinum Investment Management Ltd.” was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/12/06/dermira-inc-derm-shares-bought-by-platinum-investment-management-ltd.html.

Dermira Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Institutional Ownership by Quarter for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply